Clinical Trials Directory

Trials / Unknown

UnknownNCT01123057

Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Singapore National Eye Centre · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a hospital-based interventional prospective study. Patients with clinical keratoconus or LASIK keratectasia presenting to the Singapore National Eye Centre who meet the eligibility criteria are recruited for this study. The aim of the study is to assess the safety and efficacy of riboflavin-UVA induced cross-linking treatment for corneal ectasia

Detailed description

The purpose of this evaluation is to assess the safety and efficacy of riboflavin-UVA induced cross-linking treatment for corneal ectasia due to keratoconus and LASIK keratectasia. The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment. The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application. A thorough examination is performed to evaluate the following pre-operatively: * Manifest refraction results - Uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA) * Cycloplegic refraction results - Uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA) * Slit-lamp biomicroscopy and photography * Intraocular pressure measurement * Fundoscopy * Corneal topography using Orbscan II and Pentacam * Corneal aberrometry measurement using Technolas Zywave Aberrometer * Endothelial cell count measurement using Konan noncontact endothelial cell analyser * Confocal microscopy * Corneal hysteresis measurement using Ocular Response Analyser * Subjective feedback about quality of vision (VF 14 assessment) Post-operative Assessment (1 day, 1 week, 1 month, 3 months, 6 months and 1 year postoperatively) * Uncorrected visual acuity and best corrected visual acuity with manifest refraction * Cycloplegic refraction results - uncorrected visual acuity and best corrected visual acuity * Subjective visual outcome rating * Slit lamp examination and photography * Fundoscopy * Corneal topography * Aberrometry measurement * Endothelial cell count * Confocal microscopy * Corneal hysteresis measurement * Report adverse events

Conditions

Interventions

TypeNameDescription
PROCEDUREriboflavin-induced collagen cross-linking treatmentThe principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment. The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application.
DEVICERiboflavin-UVA induced collagen cross-linking treatment for corneal ectasiaUse of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)

Timeline

Start date
2008-08-01
Primary completion
2010-06-01
Completion
2010-06-01
First posted
2010-05-14
Last updated
2010-05-14

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT01123057. Inclusion in this directory is not an endorsement.